Leveraging Magellan Health's 50+ years of behavioral health expertise and the MRx Cares clinical coaching program, nearly 1,800 members across the United States, ranging in age from 18 to 90, who participated in the six-week program received help, support, and encouragement to maintain their daily routines, connect with loved ones, and find meaning in everyday life.
At completion, the group reported the ability to adopt and implement mindful behaviors that had a positive effect on their lives during the height of the COVID-19 pandemic.
Program participants live with a range of chronic, specialty conditions, including psoriasis, HIV, rheumatoid arthritis, and multiple sclerosis.
As a result of the pandemic and their conditions, the most common challenges participants faced were stress, lifestyle challenges, and medical concerns. The program identified each participant's level of social isolation as well as communication preferences.
On average, participants engaged in 15-20 dialogues on a variety of health- and habit-related topics delivered through text messages during a 45-day period.
Dialogues included interactive check-ins, and visual stories shared via an interactive, dynamic, and mobile-friendly microsite, in addition to one-way messages and tips.
According to recent research from mPulse, 43% of adults age 60+ in the US reported feeling lonely, well before the COVID-19 pandemic. Loneliness has been linked to a 30% increase in risk of stroke or coronary heart disease as well as an impact on levels of stress and anxiety, interference with good sleep, and effects on long-term immune functioning.
Magellan Rx Management, a division of Magellan Health, Inc., is a pharmacy organization that is delivering meaningful solutions to the people we serve.
Magellan Health is in managing areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007